How integrins control breast biology
Marina A Glukhova1 and Charles H Streuli

This article explores new ideas about how the ECM-integrin axis controls normal and malignant breast biology. We discuss the role of integrins in mammary stem cells, and how cell–matrix interactions regulate ductal and alveolar development and function. We also examine the contribution of integrins to tissue disorganisation and metastasis, and how an altered stromal and ECM tumour microenvironment affects the cancer cell niche both within primary tumours and at distant sites. Finally, we mention novel strategies for integrin-directed breast cancer treatment.

Addresses
Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, Oxford Road, Manchester M13 9PT, United Kingdom
Corresponding author: Streuli, Charles H (cstreuli@manchester.ac.uk) 1 UMR144 CNRS-Institut Curie, 26 rue d’Ulm, 75248 Paris, France.

Current Opinion in Cell Biology 2013, 25:633–641
This review comes from a themed issue on Cell adhesion and migration
Edited by Carole A Parent and Orion D Weiner
For a complete overview see the Issue and the Editorial
Available online 22nd July 2013
0955-0674 © 2013 The Authors. Published by Elsevier Ltd.
Open access under CC BY license.
http://dx.doi.org/10.1016/jceb.2013.06.010

Introduction
Building and maintaining epithelial tissues is a complex process. Even in a relatively simple organ such as mammary gland, the formation of a network of ducts and associated alveoli requires sophisticated interactions between epithelium and the surrounding microenvironment (Figure 1a,b). Ductal and alveolar breast epithelia adhere to the type of ECM known as basement membranes (BM). Stromal cells bind directly to interstitial ECM. Both local epithelial–ECM interactions and long-range communication between epithelium and stroma are essential for all aspects of normal mammary gland development and function [1–3].

The main ECM receptors of mammary epithelium are integrins, which link ECM with the cytoskeleton and signalling pathways and thereby establish an ECM-integrin-signalling axis. Integrins function as microenvironmental sensors that control cell phenotype and fate decisions [4]. They are on-off switches and rheostats, which modulate cellular responses to growth factor (GF) signals and cytokines, and convert tension forces generated within the microenvironment into intracellular chemical signals [5,6].

The prominence of integrins predicts that they will have defining roles in mammary gland biology and disease. Genetic deletion experiments reveal that integrins control nearly every aspect of mammary gland function [1,3]. Pathological and genetic studies implicate integrins in both early breast cancer and malignant disease [7,8,9]. The central role of stromal cells in mammary development and cancer also predicts key roles for integrins in the fibroblast, adipocyte and macrophage compartment of breast. However, genetic analyses have yet to explore integrin function in stromal cell types.

In this review, we focus on new ideas about how the ECM-integrin axis controls normal and malignant breast biology.

Integrins have a central role in the mammary stem cell niche
Mammary ducts are pseudo-stratified epithelia consisting of basal myoepithelial cells that contact ECM, and luminal epithelia that line the ductal lumens [1]. In vivo lineage tracing studies suggest that myoepithelial and luminal stem cells diverge at birth, and once formed they do not transition between each other [10]. Integrins are key receptors to maintain mammary stem cells within their niches. Deletion of β1-integrins from luminal cells prevents transplanted mammary epithelial fragments from forming new glands [11]. Genetic removal of β1-integrins specifically within basal myoepithelial cells affects stem cell renewal. Myoepithelial cells normally divide parallel to the plane of the BM, but in the absence of β1-integrins mitotic cells within the basal layer align their spindle poles randomly, leading to a perturbation of cell lineages and epithelial homeostasis [12**].

As microenvironmental sensors, integrins provide a mechanistic link between the stem cell niche and stem/progenitor cell fates. The β1 and β3-integrin subunits, as well as the β1 partner α2-integrin, and the β1/β4 partner α6-integrin, are used to isolate stem and progenitor cells, though their individual roles in normal mammary stem cell biology are not yet known [13,14]. In cancer, α6 and β3 integrins are expressed in tumour-initiating cells (TICs) and promote their self-renewal [15,16*,17]. For β3-integrin
at least, the mechanism is through cooperation with TGFβ [16*]. However integrins may have an additional and unique function in mammary stem cells. Placing mammary epithelia in suspension induces virtually all of the cells to undergo anoikis, because they require integrin signalling to prevent Bax-mediated death [18,19**]. In ‘mammosphere’ stem cell assays performed with cell suspensions, floating stem cells uniquely survive and proliferate to form mammospheres, which can regenerate epithelial ducts/alveoli if implanted into mammary fat pads [20].

The adhesion signalling components of the ECM-integrin axis, which provide normal mammary stem cells with the capacity of anchorage-independent growth, remain to be defined. In the Polyoma-Middle T breast cancer model, focal adhesion kinase (FAK) maintains TICs, and genetic deletion of Fak impairs tumorigenicity [21]. Integrins and GFs also co-stimulate signalling pathways to maintain stem cells. In TICs of triple-negative breast cancer, neuropilin-2 collaborates with α6β1 integrin to activate the Fak/Ras/Mek pathway and the expression of the Hedgehog effector Gli1. In turn, Gli1 induces the expression of both the stem cell regulator BMI-1 and neuropilin-2, thereby creating an autocrine loop to maintain the stem cell niche [22,23*].

Understanding the mechanisms linking integrin-mediated recognition of the stem cell niche with the profile of transcription factors that determine the identity of both normal breast stem cells and TICs is a pressing area for the future.

**Cell–matrix interactions and integrins are essential for ductal morphogenesis**

The ductal architecture of mammary gland is formed by unique mini-organs called terminal end buds, which invade stroma and bifurcate to produce a branching network of ducts [24]. Endbuds are surrounded by BM and require β1-integrins to generate motility [25]. 3D models, where duct-like structures form and elongate through ECM (i.e. Matrigel) in response to stromal GFs such as FGF2, are providing novel insights into the ductal morphogenesis programme [26]. Cells within cultured ‘endbuds’ do not extend lamellipodia in the way that migrating cells on 2D substrata do, rather the cells have smooth edges and appear to shuffle together through the ECM [27*]. Although β1-integrins are required for cultured ducts to form (Streuli lab, unpublished data), the mechanisms of integrin-dependent migration remain to be defined.

Little is known about the processes controlling branching of mammary ducts. In prepubertal gland, collagen I fibers are oriented towards the long axis of the mammary fat pad, and upon puberty, the branching epithelium follows pre-existing collagen tracks suggesting that the stroma provides spatial cues to direct branch growth [28**]. Salivary gland is related to breast, and although mammary and salivary differentiation programmes are cell autonomous, ductal patterning is controlled directly by the stroma of the host tissue [29]. This further argues that cell–matrix interactions with stromally derived ECM proteins influence branch patterns. Indeed, fibronectin assembly and the fibronectin-induced regulator Bbd7, local accumulation of tenascin, MT1-MMP, and NC1 domains of collagen-IV, as well as integrin-mediated ROCK1-myosin II, FAK and ERK signalling, all have important roles in glandular branching morphogenesis [29,30,31,32,33*].
The new imaging systems to study how ducts form, and discoveries about the GFs and ECM proteins involved, promise to offer far-reaching insights into how normal epithelial morphogenesis occurs and how it is subverted during malignancy [34*,35].

**Integrins control the differentiated function of mammary alveoli and lumen formation**

By contrast to the elongated nature of ducts, lactational alveoli are roughly spherical. Clusters of alveoli gather in terminal ductal lobular units (Figure 1a). Alveoli contain a single layer of polarised luminal epithelial cells surrounded by sparse myoepithelia — both cell types contact the basally located BM. Alveoli produce milk and secrete it apically into the luminal space, from where it is squeezed into ducts by the contraction of myoepithelial cells. Genetic analyses reveal that luminal polarity and myoepithelial contraction both require β1-integrins [36**,37**] (Figure 2a).

Interactions between laminin and integrins orient the microtubule network into an apical-basal direction by recruiting microtubule plus tips via ILK and EB1 [37**]. This triggers endocytosis of apical membrane components, leading to the formation of an apical surface at the opposite side of the cell where the lumen forms. It is not yet known how integrins organise microtubules, but possibilities include an ILK-mediated link to IQ-GAP and Dia1 [38] and/or interactions between laminin-binding integrins, the PH-domain protein LL5, and the microtubule plus-tip binding protein, Clasp [39*]. Microtubules may also dynamically regulate adhesion via the MT motor protein KIF14, which controls inside-out integrin activation via Rapil and Rap1 [40*].

Once made, milk is ejected from the alveolar lumens into ducts in response to oxytocin-induced myoepithelial contraction. The contractile force generated within cells needs an equal and opposite force from the surrounding ECM, which is transmitted through integrins. In the contraction-relaxation cycle, oxytocin induces contraction via a Rho/Rock/myosin tension pathway, while α3β1-integrin relaxes tension via Fak/Rac/Pak signalling to inhibit MLCK [36**] (Figure 2a).

**Figure 2**

(a) Diagram of a part mammary alveolus showing key functional integrin-dependent forces identified by genetic analyses. β1-integrins are required for luminal cells to orientate their polarity so that they can secrete milk apically into lumens, and for myoepithelial cells to complete the stretch-relax cycles needed for milk ejection. (b) Epithelial cell function depends on the integration a variety of microenvironmental signals, including those from GFs, cell-ECM and cell-cell interactions, and from biomechanical forces. (c) Cell-ECM interactions can regulate transcription and cell phenotype directly by a series of mechanical links between ECM, acto-myosin cytoskeleton, the LINC nuclear membrane complex, and nuclear cytoskeleton.
Integrins and tension also control gene expression in luminal cells. The BM provides essential instructive signals for mammary differentiation via β1-integrins and specific components of adhesion complexes [4]. These signals guide tissue-specific gene expression in conjunction with temporal cues from the cytokine, prolactin [41–45]. In a separate mechanism, the elasticity of the local microenvironment and its effects on intracellular tension determine the levels of prolactin receptor—tension blocks transcription of the receptor [46]. Tissue-specific gene expression is therefore controlled not only by biochemical signals, that is, soluble factors and ECM, but also by mechanical forces [47].

Thus, converging signals from the cellular microenvironment, comprising hormones, ECM proteins and stromal tension coordinate alveolar cell function (Figure 2b). Hormones and ECM respectively provide temporal and spatial cues to activate milk synthesis in the appropriate luminal cells, while perhaps expansive forces antagonise endocrine signalling to protect alveolar integrity during abstinence of suckling.

There is an emerging awareness that multiple types of signals, that is, ECM proteins, soluble factors, physical forces and cell–cell interactions, control metazoan cell function. Deconvoluting how their intracellular effectors all interconnect to specify different fates will need both refined ways for analysing single cells and systems biology approaches.

**Integrins are checkpoints for GF signalling in normal breast and cancer**

Integrins ‘integrate’ cells into their tissues by binding cells to the ECM and simultaneously organising the cytoskeleton (Figure 2c). To link to the cell interior, integrins, which have short non-enzymatic cytoplasmic tails, assemble large multi-protein machines at the plasma membrane [48]. The combined ability to bind ECM proteins and control cytoskeletal dynamics and signalling allow integrins to sense the physical and chemical nature of the microenvironment, and to adjust intracellular responses appropriately.

For example, integrins are checkpoints for the normal proliferation of mammary cells during development [11]. In culture models, β1-integrins control the outcome of EGF signalling, by activating a Rac1 signalling pathway that controls Erk nuclear import [49]. Integrins signal directly to cell cycle via the adhesion complex protein talin, which is necessary for Fak activation and p21 suppression, and thereby providing the conditions for GFs to drive cell cycle [50].

The function of integrins as adhesion checkpoints for hormone and growth factor signalling is crucial for maintaining the normal architecture and integrity of mammary tissue [5]. Correspondingly, perturbations of the integrin axis contribute to the major pathology of breast, which is cancer. Too high levels of β1-integrins, β5-integrins or β6-integrins [51–54], or too much activity of integrin signalling components, co-operate with oncogenes to drive excessive GF signalling. For example, Fak, Src and small GTPase activators Trio, Vav3 and P-Rex1 are frequently upregulated in breast cancer [55–58]. This leads to increased epithelial proliferation, or reduced apoptosis in response to damage. Other elevated adhesion complex proteins, for example, kindlin-1, contribute to advanced breast disease, including metastasis [59].

Integrin function can also alter in disease progression. α6β4-integrin is normally involved with cell adhesion to BM via hemidesmosomes and seems to be not essential for normal development [9,60]. However, in advanced breast carcinomas α6β4 relocates to the leading front of invasive cells, where it cooperates with ErbB2 and ErbB3 to promote inappropriate signalling [9,61].

Thus, as with the other classic cell cycle and apoptosis checkpoints that become deregulated in cancer, so do the integrin checkpoints. Integrins maintain tissue architecture and function in the normal breast, while disrupting the integrin axis alters signalling and causes tissue disorganisation and malignancy.

**Altered integrins cause tissue disorganisation and metastasis in breast cancer**

An early event to arise during breast cancer initiation is tissue disorganisation (Figure 1c). The luminal cells that form the majority of breast cancers undergo massive bursts of proliferation each menstrual/oestrus cycle and during pregnancy. Epithelial proliferation is spatially orchestrated in normal breast, but what distinguishes this process from cancer is that the latter is disorganised. Moreover, tumours originate initially from single cells. This has been modelled in 3D cultured breast acini by using limiting dilutions of lentiviral infection [62]. Some breast oncogenes, for example, ErbB2, cause normal surrounding cells to extrude the rogue oncogene-expressing cell into the acinar lumen, where it proliferates abnormally. Other oncogenes require assistance from a second change, for example, oncogenic Akt1 requires MT1-MMP activation or talin depletion to cause rogue cell displacement. This argues that altered cell–matrix interactions may contribute to the early stages of cancer, by disrupting the normal spatial architecture of breast ducts and lobules.

In early breast hyperplasias and in situ carcinoma, epithelial cell masses remain encapsulated by myoepithelial cells and BM, but the cells lose polarity and the discrete bi-layered organisation. Microarray data has revealed that the expression of a variety of genes encoding cell–matrix proteins is altered during the progression of early breast cancers, including atypical ductal hyperplasia and
ductal carcinoma in situ [63]. Although cell extrusion contributes to tissue disorganisation, loss of polarity also has a key role. Polarity genes are deregulated in early disease, and some, such as Par3, are potent metastasis suppressors [64,65]. Similarly, reduced levels of adhesion complex proteins that normally integrate breast epithelia within their tissue environment contribute to malignancy. For example the collagen receptor, α2β1-integrin, is a metastasis suppressor. Its levels are reduced in advanced breast cancer, and deleting the α2-integrin gene promotes metastases [66*]. Integrin signalling proteins such as nischarin and the Rho-GEFs Vav2/3 are further tumour suppressors in breast [15,16,67*,68].

The β3-integrins may contribute to tumour angiogenesis and progression of some classes of breast cancer, and although β3-integrins are expressed in mammary stem cells, their role in normal breast are not known. [69,70].

A gap in our knowledge is how levels of integrin signalling proteins change in breast cancer. Future work to dissect the impact of adhesion mutations on breast cancer, and a greater emphasis on the epigenetic control of cell–matrix adhesion is urgent, as this may provide valuable new strategies to tackle disease [71–74].

**The stromal microenvironment is a key player in breast cancer**

Breast stroma has come to the fore as a major player in tumour development [75]. The tumour microenvironment promotes the deposition of ECM proteins into cross-linked fibers, whose alignment results in a stiffer stroma and

![Figure 3](image-url)

(a) Integrins and integrin signalling proteins are upregulated or activated at the primary breast tumour site. This leads to tissue disorganisation and loss of polarity. The stromal ECM changes, becoming stiffer. Together changes in integrin signalling promote increased proliferation, reduced apoptosis, and enhanced migration. (b) Tumour cells influence cell-ECM interactions at the secondary site by remodelling the stromal niche. This can occur in a variety of ways, including direct expression of proteins normally expressed in embryogenesis (tenascin), and indirect remodelling via stromal cell intermediates, for example in the expression of periostin.
poorer prognosis for cancer (Fig. 3a) [76]. This contributes to tumorigenesis via integrin mechanosensing receptors, leading to enhanced Rho-mediated contractility and activation of integrin signalling. For example in stiff matrices, Fak promotes Mdm-2-dependent p53 degradation thereby preventing apoptosis [77]. These conditions also activate the Ras/Erk and PI3K pathways, further enhancing survival and proliferation [78].

ECM proteins that are abnormally expressed by infiltrating tumour or stromal cells promote invasion and metastasis. The laminin receptor, α6β4-integrin, regulates expression of SPARC (secreted protein acidic and rich in cysteine), which is involved with matrix remodelling [79]. SPARC is negatively controlled by miR-29a, and α6β4-integrin down-regulates this microRNA thereby enhancing SPARC expression and promoting invasion. Tenascin-C, often up-regulated in breast cancer, induces Fak/Src activation, partial EMT, enhanced migration, and quick progression to lung relapse [80]. Moreover, elevated Tenascin-C enhances expression of the stem cell regulators, musashi homolog 1 and leucine-rich repeat-containing G protein-coupled receptor 5, and promotes the growth of pulmonary micrometastases, while its knock-down diminishes lung metastases (Fig. 3b) [81**]. Finally, periostin is a stromal ECM protein that is abnormally expressed in the tumour microenvironment and in metastases [82]. To initiate lung metastases, breast cancer cells induce the expression of periostin in lung stroma [83**]. The establishment of a distant niche by stromal cells in response to paracrine tumour cell signalling appears to be an important step in metastasis formation.

These new findings about how the stroma contributes to breast cancer through altered expression of ECM proteins and assembly of ECM architecture, and how tumour cells prime the metastatic niche, profoundly change the way we think about cancer progression.

Integrin-targeted therapies for breast cancer

Taken together, integrins have a central role in regulating all aspects of mammary gland function, and perturbed integrin signalling is required for breast cancer to progress (Figure 3). The ECM–integrin axis is therefore a promising target for combatting disease [84]. Although hormone and GF antagonists are effective for some types of cancer, the more intractable cancers, for example, triple-negative malignant lesions, remain incurable. More emphasis on intervening with cell–matrix interactions will considerably augment current treatments, by targeting the TIC niche and metastases.

Some integrin-directed approaches are in pre-clinical trials. For example, anti-integrin antibodies, in combination with radiotherapy, may be showing early signs of success [85,86]. Moreover, many integrin antagonists are currently under clinical development [87]. Small molecules such as cilengitide (a cyclic anti-integrin RGD mimetic) may reduce metastatic colonisation and inhibiting bone resorption in established metastases [88,89]. Particularly exciting are the new combinatorial approaches to target cancer stromal cells: combined antagonists of monocyte α4β1 integrin and SDFs or IL-1β inhibit tumour inflammation and growth [90], and a recombinant protein jointly targeting integrins and VEGF is an effective inhibitor of breast cancer angiogenesis [91].

However, although some of these strategies target cancer cells themselves, careful use of therapies will be needed in the light of integrin’s ability to both promote cancer and to act as tumour suppressors.

Acknowledgements

Thanks to Dr Paul Lu (University of Manchester) for critical review of the manuscript. The Wellcome Trust Centre for Cell-Matrix Research is supported by core funding from the Wellcome Trust [#088785/Z/09/Z]. The work in MAG is supported by a Ligue Nationale Contre le Cancer (Equipe Labellisée 2013). MAG is Directeur de Recherche at the Institut National de la Santé et de la Recherche Médicale (INSERM).

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

• of special interest

•• of outstanding interest

1. Muschler J, Streuli CH: Cell-matrix interactions in mammary gland development and breast cancer. Cold Spring Harb Perspect Biol 2010, 2:a003202.

2. Lu P, Weaver VM, Werb Z: The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196:395-406.

3. Raymond K, Faraldo MM, Deugnier M-A, Glukhova MA: Integrins in mammary development. Semin Cell Dev Biol 2012, 23:599-605.

4. Streuli CH: Integrins and cell-fate determination. J Cell Sci 2009, 122:171-177.

5. Katz E, Streuli CH: The extracellular matrix as an adhesion checkpoint for mammary epithelial function. Int J Biochem Cell Biol 2007, 39:715-726.

6. Eyckmans J, Boudou T, Yu X, Chen CS: A hitchhiker’s guide to mechanobiology. Dev Cell 2011, 21:35-47.

7. Huck L, Pontier SM, Zuo DM, Muller WJ: beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci USA 2010, 107:15559-15564. Genetic study that reveals a requirement for β1-integrins in progression of Her2 cancers to form metastases, but integrins may not always be needed for primary tumour formation.

8. White DE, Kurpios NA, Zuo D, Hassell JA, Blaesa S, Mueller U, Muller WJ: Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumour induction. Cancer Cell 2004, 6:159-170.

9. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG: Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006, 126:489-502.

10. Van Keymeulen A, Rocha AS, Ouisset M, Beck B, Bouvencourt G, Rock J, Sharma N, Dekoninck S, Blanpain C: Distinct stem cells
Contribute to mammary gland development and maintenance. Nature 2011, 479:189-193.

11. Li N, Zhang Y, Naylor MJ, Schatzmann F, Maurer F, Wintermantel T, Schuetz G, Mueller U, Streuli CH, Hynes NE: Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. EMBO J 2005, 24:1942-1953.

12. Taddei I, Deugnier M-A, Faraldo MM, Petit V, Bouvard D, Medina D, Fassler R, Thiery JP, Glukhova MA: Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells [Internet]. Nat Cell Biol 2008, 10:716-722.

β1-integrins are essential for the maintenance of mammary stem cells and control the orientation of basal stem cell division.

13. Smalley MJ, Kendrick H, Sheridan JM, Regan JL, Prater MD, Lindeman GJ, Watson CJ, Visvader JE, Stingl J: Isolation of mouse mammary epithelial subpopulations: a comparison of leading methods. J Mammary Gland Biol Neoplasia 2012, 17:91-97.

14. Shetha M, Teschendorff A, Sharp G, Novic N, Russell IA, Avril S, Prater M, Eirew P, Caldas C, Watson CJ et al.: Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res 2012, 14:R134.

15. Vaillant F, Asselin-Labat M-L, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE: The mammary progenitor marker CD61/β3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 2008, 68:7711-7717.

16. Lo P-K, Kanojia D, Liu X, Singh UP, Berger FG, Wang Q, Chen H: CD49d and CD61 identity Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling. Oncogene 2012, 31:2614-2626.

β3-integrin signaling has a role in the TGFβ-dependent self-renewal of TICs in MMTV-Her2/neu mouse mammary tumours.

17. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, Purushotham AD: Alpha-6 integrin is necessary for the tumorigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008, 122:298-304.

18. Gilmore AP, Metcalfe AD, Romer LH, Streuli CH: Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. J Cell Biol 2000, 149:431-446.

19. Schellenberg B, Wang P, Keeble JA, Rodriguez-Enriquez R, Walker S, Owens TW, Foster F, Brennan K, Streuli CH et al.: Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming. Mol Cell 2013, doi:10.1016/j.molcel.2012.12.022.

This study re-examines how adhesion signalling controls intrinsic Bax-mediated apoptosis in mammary epithelia.

20. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giuliani B, Briken C, Minucci S, Di Fiore PP, Pellicci PG: The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009, 138:1083-1095.

21. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, Wicha MS, Guan J-L: Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res 2009, 69:467-446.

22. Goel HL, Pursell B, Standley C, Fogarty K, Mercurio AM: Neuroplatin-2 regulates α6β1 integrin in the formation of focal adhesions and signaling. J Cell Sci 2012, 125:497-506.

23. Goel HL, Pursell B, Chang C, Shaw LM, Mao J, Simin K, Kumar P, Kooi CWV, Shultz LD, Greiner DL et al.: GL1 regulates a novel neuroplatin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med 2013 http://dx.doi.org/10.1002/emmm.201202078. The paper describes how TICs maintain their niche via an autocrine loop involving neuroplatin 2 and α6β1 integrin signalling.

24. Hinck L, Silberstein GB: Key stages in mammary gland development: the mammary end bud as a motile organ. Breast Cancer Res 2005, 7:245.

25. Klinowska TC, Soriano JV, Edwards GM, Oliver JM, Valentin AJ, Montesano R, Streuli CH: Laminin and beta1 integrins are crucial for normal mammary gland development in the mouse. Dev Biol 1999, 215:13-32.

26. Lu P, Ewald AJ, Martin GR, Werb Z: Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev Biol 2008, 321:77-87.

27. Ewald AJ, Brenot A, Duong M, Chan BS, Werb Z: Collective epithelial migration and cell rearrangements drive mammary branching morphogenesis. Dev Cell 2008, 14:570-581. Describes a 3D culture system to model the development of primary mammary epithelial ducts.

28. Brownfield DG, Venugopalan G, Lo A, Mori H, Tanner K, Fletcher DA, Bissell MJ: Patterned Collagen fibers orient branching mammary epithelium through distinct signaling modules. Current Biology 2013, 23:703-709. The study demonstrates that the tracks of stromal collagen fibres guide the growth of mammary branches.

29. Sakakura T, Nishizuka Y, Dawe CJ: Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentiation in mouse mammary gland. Science 1976, 194:1439-1441.

30. Ondera T, Sakai T, Hsu JC, Matsumoto K, Chiorini JA, Yamada KM: Beta7 regulates epithelial cell dynamics and branching morphogenesis. Science 2010, 328:562-565.

31. Daley WP, Kohn JM, Larsen M: A focal adhesion protein-based mechanochemical checkpoint regulates cleft progression during branching morphogenesis. Dev Dyn 2011, 240:2068-2083.

32. Rebustini IT, Myers C, Lasitter KS, Surmak A, Szabova L, Holmbeck K, Pedchenko V, Hudson BG, Hoffman MP: MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis. Dev Cell 2009, 17:482-493.

33. Mori H, Lo AT, Inman JL, Alcaraz J, Ghajjar CM, Mott JD, Nelson CM, Chen CS, Zhang H, Bascom JL et al.: Transmembrane/cytosplasmic, rather than catalytic, domains of Mmp14 signal to MAPK activation and mammary branching morphogenesis via binding to integrin β1. Development 2013, 140:343-352. Direct association of a transmembrane metalloproteinase Mmp14 with integrin β1 is shown to contribute to integrins activation required for mammary branching morphogenesis.

34. Nguyen-Ngoc K-V, Cheung KJ, Brenot A, Shamir ER, Gray RS, Chisholm MJ, Grizzle WE, Ewald AJ: ECM microenvironment regulates collective migration and local distribution in normal and malignant mammary epithelium. Proc Natl Acad Sci USA 2012, 109:E2595-E2604. This study uses ECM gels to show that metastatic tumour dissemination strongly depends on the specific ECM microenvironment.

35. Yoshida T, Matsumoto E, Hanamura N, Kalembeiyi I, Katsuta K, Ishihara A, Sakakura T: Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. J Pathol 1997, 182:421-428.

36. Raymond K, Cagnet S, Kreft M, Janssen H, Sonnenberg A, Glukhova MA: Control of mammary myoepithelial cell contractile function by α3β1 integrin signalling. EMBO J 2011, 30:1896-1906. Genetic study identifies α3-integrin as a key player in physiological contraction of myoepithelial cells during lactation.

37. Akhtar N, Streuli CH: An integrin-ILK-microtubule network orients cell polarity and lumen formation in glandular epithelium. Nat Cell Biol 2013, 15:17-27. Cell-ECM interactions determine the orientation of polarity in mammary epithelia via a link between β1-integrins and microtubules.

38. Wickström SA, Lange A, Hess MW, Polleux J, Spatz JP, Krüger M, Pfaller K, Lambacher A, Bloch W, Mann M et al.: Integrin-linked kinase controls microtubule dynamics required for plasma membrane targeting of caveolae. Dev Cell 2010, 19:574-588.

39. Hotta A, Kawakatsu T, Nakatani T, Sato T, Matsui C, Sukezane T, Akagi T, Hamaji T, Grigoriev I, Akhmanova A et al.: Laminin-based
cell adhesion anchors microtubule plus ends to the epithelial cell basal cortex through LL5alpha/beta. J Cell Biol 2010, 189:901-917.

LL5 and Clasp are shown to be key links between laminin-integrins and microtubules in mammary epithelial cells.

40. Ahmed SM, Thériault BL, Uppalapati M, Chiu CWN, Gallie BL, • Sidhu SS, Angers S: KIF14 negatively regulates Rap1a-Radl signaling during breast cancer progression. J Cell Biol 2012, 199:951-967.

This work suggests that up-regulation of Rap1 activity and increased KIF14 levels are needed to reach optimal levels of Rap1-Radl signalling, integrin activation, and cell–matrix interactions required for tumour progression.

41. Naylor MJ, Li N, Cheung J, Lowe ET, Lambert E, Marlow R, Wang P, Schatzmann F, Wintermantel T, Schuetz G et al.: Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J Cell Biol 2005, 171:717-728.

42. Akhtar N, Streuli CH: Rac1 links integrin-mediated adhesion to the control of facultational differentiation in mammary epithelia. J Cell Biol 2006, 173:781-793.

43. Akhtar N, Marlow R, Lambert E, Schatzmann F, Lowe ET, Cheung J, Katz E, Li W, Wu C, Dedhar S et al.: Molecular dissection of integrin signalling proteins in the control of mammary epithelial development and differentiation. Development 2009, 136:1019-1027.

44. Edwards GM, Wilford FH, Liu X, Hennighausen L, Dijane J, Streuli CH: Regulation of mammary differentiation by extracellular matrix polarity proteins involves tyrosine phosphatases. J Biol Chem 1998, 273:9495-9500.

45. Zoubiane GS, Valentijn A, Lowe ET, Akhtar N, Bagley S, Gilmore AP, Streuli CH: A role for the cytokskeleton in prolactin-dependent mammary epithelial cell differentiation. J Cell Sci 2004, 117:271-280.

46. Du J-Y, Chen M-C, Hu T-C, Wang J-H, Brackenbury L, Lin T-H, • Wu Y-Y, Yang Z, Streuli CH, Lee Y-J: The RhoA-Rok-moyisin II pathway is involved in extracellular matrix-mediated regulation of prolactin signalling in mammary epithelial cells. J Cell Physiol 2012, 227:1553-1560.

Shows that intracellular tension controls transcription in mammary epithelia.

47. Mamotto A, Mamotto T, Ingber DE: Mechanosensitive mechanisms in transcriptional regulation. J Cell Sci 2012 http://dx.doi.org/10.1242/jcs.093005.

48. Streuli CH, Akhtar N: Signal co-operation between integrins and other receptor systems. Biochem J 2009, 418:491-506.

49. Jeanes AI, Wang P, Moreno-Layseca P, Paul N, Cheung J, Tsang R, Akhtar N, Foster FM, Brennan K, Streuli CH: Specific β-containing integrins exert differential control on proliferation and two-dimensional collective cell migration in mammary epithelial cells. J Biol Chem 2012, 287:24103-24112.

50. Wang P, Ballestre CM, Streuli CH: The C terminus of talin links integrins to cell cycle progression. J Cell Biol 2011, 192:499-513.

The proximal link between adhesion and cell cycle in mammary cells is the integrin-binding protein, talin.

51. Dos Santos PB, Zenotti JS, Ribeiro-Silva A, Beltrao EI: Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagn Pathol 2012, 7:104.

52. Yao ES, Zhang H, Chen Y-Y, Lee B, Chew K, Moore D, Park C: Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 2007, 67:659-664.

53. Bianchi-Smiraglia A, Paesante S, Bakin AV: Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene 2012. doi:10.1038/onc.2012.320.

54. Goodman SL, Grote HJ, Wilm C: Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Bioi Open 2012, 1:329-340.

55. Lane J, Martin TA, Mansel RE, Jiang WG: The expression and prognostic value of the guanine nucleotide exchange factors (GEFα) Trio, Vav1 and TIAM-1 in human breast cancer. Int Seminars Surg Oncol 2008:5.

56. Lee K, Liu Y, Mo JQ, Zhang J, Dong Z, Lu S: Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer 2008, 8:158.

57. Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM, Luo J, Benovic JL, Klein-Szanto A, Yagi H et al.: Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell 2010, 40:877-892.

58. Zouq NK, Kebbie JA, Lindsay J, Valentijn AJ, Zhang L, Mills D, Turner CE, Streuli CH, Green AP: FAK engages multiple pathways to maintain survival of fibroblasts and epithelia: differential roles for paxillin and p130Cas. J Cell Sci 2009, 122:357-367.

59. Sin S, Bonin F, Petit V, Meseure D, Lallemend F, Bleche I, • Bellahcene A, Castronovo V, De Wever O, Gespal C et al.: Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. J Natl Cancer Inst 2011, 103:1323-1337.

The study characterises the role of integrin-associated protein kindlin in lung metastasis in breast cancer.

60. Klinowska TC, Alexander CM, Georges-Labouesse E, Van der Neut R, Kneidberg JA, Jones CJ, Sonnenberg A, Streuli CH: Epithelial development and differentiation in the mammary gland is not dependent on alpha 3 or alpha 6 integrin subunits. Dev Biol 2001, 233:449-467.

61. Lu S, Simkin K, Khan A, Mercurio AM: Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res 2008, 14:1050-1058.

62. Leung CT, Brugge JS: Outgrowth of single oncogene-expressing cells from suppressive epithelial environments. Nature 2012, 482:410-413.

63. Emery LA, Tripathi A, King C, Kavanah M, Mendez J, Stone MD, Dias Morenas A, Sebastiani P, Rosenberg CL: Early dysregulation of breast cell adhesion and extracellular matrix pathways in breast cancer progression. Am J Pathol 2009, 175:1292-1302.

64. McCaffrey LM, Montalbano J, Mihai C, Macara IG: Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis. Cancer Cell 2012, 22:601-614.

65. Xue B, Krishnamurthy K, Allred DC, Muthuswamy SK: Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. Nat Cell Biol 2012, 15:189-200.

66. Ramirez NE, Zhang Z, Madamarachi N, Boyd KL, O’Rear LD, • Nashabi A, Li Z, Dupont WD, Zijlstra A, Zutter MM: The αvβ3 integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011, 121:226-237.

αβ3-1 integrin is identified as a metastasis suppressor in breast cancer.

67. Baranwal S, Wang Y, Rathinam R, Lee J, Jin L, McGoe R, Palyavea Y, Giancotti F, Blobe GC, Alahari SK: Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. J Natl Cancer Inst 2011, 103:1513-1528.

Nischarin, an αv-integrin-binding protein, is shown to be a tumour-suppressor and regulator of integrin signalling essential for tumorigenesis – FAK and Rac activation.

68. Citterio C, Menacho-Márquez M, Garcia-Escudero R, Larive RM, Barreiro G, Sánchez-Madrid F, Paramio JM, Bustelo XR: The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells. Sci Signal 2012, 5ra71.

69. Robinson SD, Hodivala-Dike KM: The role of β3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 2011, 23:630-637.

70. Taverna D, Crowley D, Connolly M, Bronson RT, Hynes RO: A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res 2005, 65:10324-10329.
How integrins control breast biology

Glukhova and Streuli

641

71. Yang X, Pursell B, Lu S, Chang T-K. Mercurio AM: Regulation of beta 4-integrin expression by epigenetic modifications in the mammary gland and during the epithelial-to-mesenchymal transition. J Cell Sci 2009, 122:2473-2480.

72. Mostoviovich LA, Prudnikova TY, Kondratov AG, Logina D, Vavilov PV, Rykova VI, Sidorov SV, Pavlova TV, Kashuba VI, Zabarovsky ER et al.: Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors. Cell Adh Migr 2011, 5:395-401.

73. Mulder KW, Wang X, Escriu C, Ito Y, Schwarz RF, Gillis J, Sirokmaný G, Donati G, Uribe-Lewis S, Pavlidis P et al.: Diverse epigenetic strategies interact to control epidermal differentiation. Nat Cell Biol 2012, 14:753-763.

74. Shah SP, Roth A, Goya R, Olouni A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Hattari G et al.: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.

75. DuFort CC, Paszek MJ, Weaver VM: Balancing forces: architectural control of mechanotransduction. Nat Rev Mol Cell Biol 2011, 12:308-319.

76. Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Elicheir KW, Provenzano PP, Friedl A, Keely PJ: Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 2011, 178:1221-1232.

The discrete architecture of ECM deposition in mammary stroma is prognostic for cancer.

77. Lim S-T, Chen XL, Lim Y, Hanson DA, Vo T-T, Howerton K, Larrocque N, Fisher SJ, Schlaper DD, Ilic D: Nuclear FAK: promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell 2008, 29:9-22.

78. Provenzano PP, Keely PJ: Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and Rho GTPase signaling. J Cell Sci 2011, 124:1195-1205.

79. Gerson KD, Shearstone JR, Maddula VSPK, Seligmann BE, Mercurio AM: Integrin b4 regulates SPARC protein to promote invasion. J Biol Chem 2012, 287:9835-9844.

80. Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, Kozuka Y, Ogawa T, Shiraishi T, Imanaka-Yoshida K: Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol 2011, 178:754-763.

81. Oskarsson T, Acharyya S, Zhang XH-F, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Masagù J: Breast cancer cells produce tenasin C as a metastatic niche component to colonize the lungs. Nat Med 2011, 17:867-874.

TN-C is implicated in TIC maintenance and lung metastasis.

82. Kharaisihii G, Cizkova M, Bouchalova K, Mgebrishvili G, Kolar Z, Bouchal J: Collagen triple helix repeat containing 1 protein, peristin and versican in primary and metastatic breast cancer: an immunohistochemical study. J Clin Pathol 2011, 64:977-982.

83. Malanchi I, Santamaria-Martinez A, Susam E, Peng H, Lehr H-A, Deloye J-F, Huelken J: Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.

Peristin is identified as an essential component of stromal metastatic niche.

84. Barkan D, Chambers AF: b1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res 2011, 17:7219-7223.

85. Nam J-M, Onodera Y, Bissell MJ, Park CC: Breast cancer cells in three-dimensional culture display an enhanced radioreponse after coordinate targeting of integrin alphaSbeta1 and fibronectin. Cancer Res 2010, 70:5238-5248.

86. Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ: Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts [Internet]. Cancer Res 2008, 68:4398-4405.

87. Goodman SL, Picard M: Integrins as therapeutic targets. Trends Pharmacol Sci 2012, 33:406-412.

88. Bretsch M, Merz M, Komiljenovic D, Berger MR, Semmler W, Baüerle T: Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncof. Rep 2011, 28:843-851.

89. Baüerle T, Komiljenovic D, Merz M, Berger MR, Goodman SL, Semmler W: Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer 2011, 128:2453-2462.

90. Schmid MC, Avraamides JC, Foubert P, Shaked Y, Kang SW, Kerbel RS, Varner JA: Combined blockade of integrin–a4,b1 plus cytokines SDF-1a or IL-1b potently inhibits tumor inflammation and growth. Cancer Res 2011, 71:6965-6975.

91. Wu J, Jiang Y, Yang W, He Z, Meng S, Zhang Q, Lin M, Zhang H, Li W, Yang Y et al.: Dual function of RGD-modified VEGF-192 for breast cancer treatment. Bioconjug Chem 2012, 23:796-804.